Amgen’s Mvasi Biosimilar Survives Restraining Order Bid Again
US Appeals Court Denies Genentech Request For Injunction On Bevacizumab
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
You may also be interested in...
Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.
Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.
Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.